Table 4 Biometric, lipoprotein profile distributions, assessment-insulin resistance and blood glucose distributions in relation to the PPARγ C161→T genotypes in CAD patients

Age

62.40 ± 12.04

67.75 ± 11.18

63.00 ± 8.73

66.80 ± 10.12

Weight (kg)

62.93 ± 9.59

58.23 ± 7.13

58.67 ± 7.51

58.32 ± 6.9 2

Height (m)

1.61 ± 0.07

1.63 ± 0.09

1.61 ± 0.06

1.63 ± 0.08

BMI (kg/m²)

22.48 ± 6.60

21.79 ± 3.14

23.01 ± 3.14

22.05 ± 3.06

TC (mmol/L)

4.37 ± 1.32

4.76 ± 1.36

3.82 ± 0.88

4.57 ± 1.31

Trig (mmol/L)

1.65 ± 0.89

1.51 ± 0.85

1.70 ± 0.82

1.55 ± 0.82

HDL (mmol/L)

1.21 ± 0.23

1.58 ± 0.62

1.13 ± 0.18

1.49 ± 0.59

LDL (mmol/L)

2.82 ± 0.69

2.77 ± 1.05

2.09 ± 0.60

2.63 ± 0.99

apoA1 (g/L)

1.29 ± 0.17

1.39 ± 0.22

1.27 ± 0.08

1.37 ± 0.20

apoB (g/L)

1.08 ± 0.11

0.87 ± 0.29

0.74 ± 0.28

0.85 ± 0.29

Lp(a) (mg/L) ^Δ

1.90 ± 0.64

1.89 ± 0.58

1.25 ± 0.03

1.78 ± 0.58

FBS (mmol/L)

5.49 ± 0.77

5.78 ± 0.75

5.46 ± 1.06

5.71 ± 0.79

PPBS (mmol/L)

6.38 ± 1.22

8.17 ± 2.03

6.87 ± 0.28

7.87 ± 1.85

RI ^Δ

1.08 ± 0.16

1.03 ± 0.21

1.12 ± 0.14

1.05 ± 0.19